Detection of Cross-Resistance Between Methotrexate and Azoles in Candida albicans and Meyerozyma guilliermondii: An In Vitro Study
Abstract
Keywords
References
Abolmaali, S. S., Tamaddon, A. M., & Dinarvand, R. (2013). A review of therapeutic challenges and achievements of methotrexate delivery systems for treatment of cancer and rheumatoid arthritis. Cancer Chemotherapy and Pharmacology, 71(5), 1115–1130. https://doi.org/10.1007/s00280-012-2062-0
Ademe, M., & Girma, F. (2020). Candida auris: From multidrug resistance to pan-resistant strains. Infection and Drug Resistance, 13, 1287–1294. https://doi.org/10.2147/IDR.S249864
Ahangarkani, F., Badali, H., Rezai, M. S., Shokohi, T., Abtahian, Z., Nesheli, H. M., Karami, H., Roilides, E., & Tamaddoni, A. (2019). Candidemia due to Candida guilliermondii in an immunocompromised infant: A case report and review of literature. Current Medical Mycology, 5(1), 32–36. https://doi.org/10.18502/cmm.5.1.535
Antonovics, J., Abbate, J. L., Baker, C. H., Daley, D., Hood, M. E., Jenkins, C. E., Johnson, L. J., Murray, J. J., Panjeti, V., Rudolf, V. H. W., Sloan, D., & Vondrasek, J. (2007). Evolution by any other name: Antibiotic resistance and avoidance of the e-word. PLoS Biology, 5(2), Article e30. https://doi.org/10.1371/journal.pbio.0050030
Arastehfar, A., Daneshnia, F., Najafzadeh, M. J., Hagen, F., Mahmoudi, S., Salehi, M., Zarrinfar, H., Namvar, Z., Zareshahrabadi, Z., Khodavaisy, S., Zomorodian, K., Pan, W., Theelen, B., Kostrzewa, M., Boekhout, T., & Lass-Flörl, C. (2020). Evaluation of molecular epidemiology, clinical characteristics, antifungal susceptibility profiles, and molecular mechanisms of antifungal resistance of Iranian Candida parapsilosis species complex blood isolates. Frontiers in Cellular and Infection Microbiology, 10, Article 206. https://doi.org/10.3389/fcimb.2020.00206
Arendrup, M. C., Meletiadis, J., Mouton, J. W., Lagrou, K., Hamal, P., & Guinea, J. (2020). EUCAST DEFINITIVE DOCUMENT E.DEF 7.3.2. Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts. https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/AFST/Files/ EUCAST_E_Def_7.3.2_Yeast_testing_definitive_revised_2020.pdf
Bello, A. E., Perkins, E. L., Jay, R., & Efthimiou, P. (2017). Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis. Open Access Rheumatology: Research and Reviews, 9, 67–79. https://doi.org/10.2147/OARRR.S131668
Ben-Ami, R. (2018). Treatment of invasive candidiasis: A narrative review. Journal of Fungi, 4(3), Article 97. https://doi.org/10.3390/jof4030097
Ben-Yaacov, R., Knoller, S., Caldwell, G. A., Becker, J. M., & Koltin, Y. (1994). Candida albicans gene encoding resistance to benomyl and methotrexate is a multidrug resistance gene. Antimicrobial Agents and Chemotherapy, 38(4), 648–652. https://doi.org/10.1128/aac.38.4.648
Berkow, E. L., & Lockhart, S. R. (2017). Fluconazole resistance in Candida species: A current perspective. Infection and Drug Resistance, 10, 237–245. https://doi.org/10.2147/IDR.S118892
Bongomin, F., Gago, S., Oladele, R. O., & Denning, D. W. (2017). Global and multi-national prevalence of fungal diseases – Estimate precision. Journal of Fungi, 3(4), Article 57. https://doi.org/10.3390/jof3040057
Brody, T. (2016). Inclusion/exclusion criteria, stratification, and subgroups – Part I. In Clinical trials (2nd ed., pp. 83–113). Academic Press. https://doi.org/10.1016/b978-0-12-804217-5.00004-7
Castanheira, M., Deshpande, L. M., Davis, A. P., Rhomberg, P. R., & Pfaller, M. A. (2017). Monitoring antifungal resistance in a global collection of invasive yeasts and molds: Application of CLSI epidemiological cutoff values and whole-genome sequencing analysis for detection of azole resistance in Candida albicans. Antimicrobial Agents and Chemotherapy, 61(10), Article e00906-17. https://doi.org/10.1128/AAC.00906-17
Castillo-Bejarano, J. I., Tamez-Rivera, O., Mirabal-García, M., Luengas-Bautista, M., Montes-Figueroa, A. G., Fortes-Gutiérrez, S., & González-Saldaña, N. (2020). Invasive candidiasis due to Candida guilliermondii complex: Epidemiology and antifungal susceptibility testing from a third-level pediatric center in Mexico. Journal of the Pediatric Infectious Diseases Society, 9(3), 404–406. https://doi.org/10.1093/JPIDS/PIAA043
Choi, M. J., Won, E. J., Shin, J. H., Kim, S. H., Lee, W. G., Kim, M. N., Lee, K., Shin, M. G., Suh, S. P., Ryang, D. W., & Im, Y. J. (2016). Resistance mechanisms and clinical features of fluconazole-nonsusceptible Candida tropicalis isolates compared with fluconazole-less-susceptible isolates. Antimicrobial Agents and Chemotherapy, 60(6), 3653–3661. https://doi.org/10.1128/AAC.02652-15
Cleveland, A. A., Farley, M. M., Harrison, L. H., Stein, B., Hollick, R., Lockhart, S. R., Magill, S. S., Derado, G., Park, B. J., & Chiller, T. M. (2012). Changes in incidence and antifungal drug resistance in candidemia: Results from population-based laboratory surveillance in Atlanta and Baltimore, 2008–2011. Clinical Infectious Diseases, 55(10), 1352–1361. https://doi.org/10.1093/cid/cis697
Clinical and Laboratory Standards Institute. (2017). M27Ed4: Reference method for broth dilution antifungal susceptibility testing of yeasts, 4th edition. https://clsi.org/standards/products/microbiology/documents/m27/
Cowen, L. E., Sanglard, D., Howard, S. J., Rogers, P. D., & Perlin, D. S. (2015). Mechanisms of antifungal drug resistance. Cold Spring Harbor Perspectives in Medicine, 5(7). https://doi.org/10.1101/cshperspect.a019752
Cretella, D., Barber, K. E., King, S. T., & Stover, K. R. (2016). Comparison of susceptibility patterns using commercially available susceptibility testing methods performed on prevalent Candida spp. Journal of Medical Microbiology, 65(12), 1445–1451. https://doi.org/10.1099/jmm.0.000383
Delaloye, J., & Calandra, T. (2014). Invasive candidiasis as a cause of sepsis in the critically ill patient. Virulence, 5(1), 154–162. https://doi.org/10.4161/viru.26187
de Oliveira Santos, G. C., Vasconcelos, C. C., Lopes, A. J. O., de Sousa Cartágenes, M. d. S., Filho, A. K. D. B., do Nascimento, F. R. F., Ramos, R. M., Pires, E. R. R. B., de Andrade, M. S., Rocha, F. M. G., & de Andrade Monteiro, C. (2018). Candida infections and therapeutic strategies: Mechanisms of action for traditional and alternative agents. Frontiers in Microbiology, 9, Article 1351. https://doi.org/10.3389/fmicb.2018.01351
Deorukhkar, S. C., Saini, S., & Mathew, S. (2014). Non-albicans Candida infection: An emerging threat. Interdisciplinary Perspectives on Infectious Diseases, 2014, Article 615958. https://doi.org/10.1155/2014/615958
European Society of Clinical Microbiology and Infectious Diseases. (2020). EUCAST: Clinical breakpoints for antifungals. https://www.eucast.org/astoffungi/clinicalbreakpointsforantifungals/
Guinea, J. (2014). Global trends in the distribution of Candida species causing candidemia. Clinical Microbiology and Infection, 20(6), 5–10. https://doi.org/10.1111/1469-0691.12539
Hagner, N., & Joerger, M. (2010). Cancer chemotherapy: Targeting folic acid synthesis. Cancer Management and Research, 2, 293–301. https://doi.org/10.2147/CMAR.S10043
Holmes, A. R., Cardno, T. S., Strouse, J. J., Ivnitski-Steele, I., Keniya, M. V., Lackovic, K., Monk, B. C., Sklar, L. A., & Cannon, R. D. (2016). Targeting efflux pumps to overcome antifungal drug resistance. Future Medicinal Chemistry, 8(12), 1485–1501. https://doi.org/10.4155/fmc-2016-0050
Huennekens, F. M. (1994). The methotrexate story: A paradigm for development of cancer chemotherapeutic agents. Advances in Enzyme Regulation, 34(C). https://doi.org/10.1016/0065-2571(94)90025-6
Jensen, R. H. (2016). Resistance in human pathogenic yeasts and filamentous fungi: Prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment. Danish Medical Journal, 63(10), Article B5288.
Jensen, R. H., Johansen, H. K., Søes, L. M., Lemming, L. E., Rosenvinge, F. S., Nielsen, L., Olesen, B., Kristensen, L., Dzajic, E., Astvad, K. M. T., & Arendrup, M. C. (2016). Posttreatment antifungal resistance among colonizing Candida isolates in candidemia patients: Results from a systematic multicenter study. Antimicrobial Agents and Chemotherapy, 60(3), 1500–1508. https://doi.org/10.1128/AAC.01763-15
Kohli, A., Gupta, V., Krishnamurthy, S., Hasnain, E., & Prasad, R. (2001). Specificity of drug transport mediated by CaMDR1: A major facilitator of Candida albicans. Journal of Biosciences, 26(3), 333–339. https://doi.org/10.1007/bf02703742
Marcos-Zambrano, L. J., Puig-Asensio, M., Pérez-García, F., Escribano, P., Sánchez-Carrillo, C., Zaragoza, O., Padilla, B., Cuenca-Estrella, M., Almirante, B., Martín-Gómez, M. T., Muñoz, P., Bouza, E., & Guinea, J. (2017). Candida guilliermondii complex is characterized by high antifungal resistance but low mortality in 22 cases of candidemia. Antimicrobial Agents and Chemotherapy, 61(7), Article e00099-17. https://doi.org/10.1128/AAC.00099-17
Matthaiou, D. K., Christodoulopoulou, T., & Dimopoulos, G. (2015). How to treat fungal infections in ICU patients. BMC Infectious Diseases, 15, Article 205. https://doi.org/10.1186/s12879-015-0934-8
Nakazawa, M., Paller, C., & Kyprianou, N. (2017). Mechanisms of therapeutic resistance in prostate cancer. Current Oncology Reports, 19(2), Article 13. https://doi.org/10.1007/s11912-017-0568-7
Nayak, R. R., Alexander, M., Stapleton-Grey, K., Ubeda, C., Scher, J. U., & Turnbaugh, P. J. (2019). Perturbation of the human gut microbiome by a non-antibiotic drug contributes to the resolution of autoimmune disease. BioRxiv. https://doi.org/10.1101/600155
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., Zaoutis, T. E., & Sobel, J. D. (2016). Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 62(4), e1–e50. https://doi.org/10.1093/cid/civ933
Polańska, A., Dańczak-Pazdrowska, A., Żaba, R., & Adamski, Z. (2016). The use of methotrexate in the treatment of selected autoimmune connective tissue diseases-our own experience and review of the literature data. Forum Dermatologicum, 4(2), 165–170.
Rocha, M. F. G., Alencar, L. P., Paiva, M. A. N., Melo, L. M., Bandeira, S. P., Ponte, Y. B., Sales, J. A., Guedes, G. M. M., Castelo-Branco, D. S. C. M., Bandeira, T. J. P. G., Cordeiro, R. A., Pereira-Neto, W. A., Brandine, G. S., Moreira, J. L. B., Sidrim, J. J. C., & Brilhante, R. S. N. (2016). Cross-resistance to fluconazole induced by exposure to the agricultural azole tetraconazole: An environmental resistance school? Mycoses, 59(5), 281–290. https://doi.org/10.1111/myc.12457
Roszkiewicz, J., Michałek, D., Ryk, A., Swacha, Z., Szmyd, B., & Smolewska, E. (2020). The impact of single nucleotide polymorphisms in ADORA2A and ADORA3 genes on the early response to methotrexate and presence of therapy side effects in children with juvenile idiopathic arthritis: Results of a preliminary study. International Journal of Rheumatic Diseases, 23(11), 1505–1513. https://doi.org/10.1111/1756-185X.13972
Roszkiewicz, J., Michałek, D., Ryk, A., Swacha, Z., Szmyd, B., & Smolewska, E. (2021). SLCO1B1 variants as predictors of methotrexate-related toxicity in children with juvenile idiopathic arthritis. Scandinavian Journal of Rheumatology, 50(3), 213–217. https://doi.org/10.1080/03009742.2020.1818821
Scorzoni, L., de Paula e Silva, A. C. A., Marcos, C. M., Assato, P. A., de Melo, W. C. M. A., de Oliveira, H. C., Costa-Orlandi, C. B., Mendes-Giannini, M. J. S., & Fusco-Almeida, A. M. (2017). Antifungal therapy: New advances in the understanding and treatment of mycosis. Frontiers in Microbiology, 8, Article 36. https://doi.org/10.3389/fmicb.2017.00036
Sharafutdinov, I. S., Ozhegov, G. D., Sabirova, A. E., Novikova, V. V., Lisovskaya, S. A., Khabibrakhmanova, A. M., Kurbangalieva, A. R., Bogachev, M. I., & Kayumov, A. R. (2020). Increasing susceptibility of drug-resistant Candida albicans to fluconazole and terbinafine by 2(5H)-furanone derivative. Molecules, 25(3), Article 642. https://doi.org/10.3390/molecules25030642
Sipsas, N. V., & Kontoyiannis, D. P. (2012). Invasive fungal infections in patients with cancer in the intensive care unit. International Journal of Antimicrobial Agents, 39(6), 464–471. https://doi.org/10.1016/j.ijantimicag.2011.11.017
Sulavik, M. C., Houseweart, C., Cramer, C., Jiwani, N., Murgolo, N., Greene, J., Didomenico, B., Shaw, K. J., Miller, G. H., Hare, R., & Shimer, G. (2001). Antibiotic susceptibility profiles of Escherichia coli strains lacking multidrug efflux pump genes. Antimicrobial Agents and Chemotherapy, 45(4), 1126–1136. https://doi.org/10.1128/AAC.45.4.1126-1136.2001
Tseng, T.-Y., Chen, T.-C., Ho, C.-M., Lin, P.-C., Chou, C.-H., Tsai, C.-T., Wang, J.-H., Chi, C.-Y., & Ho, M.-W. (2018). Clinical features, antifungal susceptibility, and outcome of Candida guilliermondii fungemia: An experience in a tertiary hospital in mid-Taiwan. Journal of Microbiology, Immunology and Infection, 51(4), 552–558. https://doi.org/10.1016/j.jmii.2016.08.015
van Soest, R. J., De Morrée, E. S., Kweldam, C. F., de Ridder, C. M. A., Wiemer, E. A. C., Mathijssen, R. H. J., de Wit, R., & van Weerden, W. M. (2015). Targeting the androgen receptor confers in vivo cross-resistance between enzalutamide and docetaxel, but not cabazitaxel, in castration-resistant prostate cancer. European Urology, 67(6), 981–985. https://doi.org/10.1016/j.eururo.2014.11.033
Wiederhold, N. P. (2017). Antifungal resistance: Current trends and future strategies to combat. Infection and Drug Resistance, 10, 249–259. https://doi.org/10.2147/IDR.S124918
Wielinga, P., Hooijberg, J. H., Gunnarsdottir, S., Kathmann, I., Reid, G., Zelcer, N., van der Born, K., de Haas, M., van der Heijden, I., Kaspers, G., Wijnholds, J., Jansen, G., Peters, G., & Borst, P. (2005). The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Cancer Research, 65(10), 4425–4430. https://doi.org/10.1158/0008-5472.CAN-04-2810
Yang, J., Gao, L., Yu, P., Kosgey, J. C., Jia, L., Fang, Y., Xiong, J., & Zhang, F. (2019). In vitro synergy of azole antifungals and methotrexate against Candida albicans. Life Sciences, 235, Article 116827. https://doi.org/10.1016/j.lfs.2019.116827
Yapar, N. (2014). Epidemiology and risk factors for invasive candidiasis. Therapeutics and Clinical Risk Management, 10, 95–105. https://doi.org/10.2147/TCRM.S40160
Yeoh, S. F., Lee, T. J., Chew, K. L., Lin, S., Yeo, D., & Setia, S. (2018). Echinocandins for management of invasive candidiasis in patients with liver disease and liver transplantation. Infection and Drug Resistance, 11, 805–819. https://doi.org/10.2147/IDR.S165676
DOI: https://doi.org/10.5586/am.566
|
|
|